Liraglutide
Clinical evidenceThe daily GLP-1 that proved the whole idea, then got outshone by its weekly successors.
What it is
Liraglutide is a 31-amino-acid GLP-1 receptor agonist — the same hormone pathway semaglutide uses, but engineered for a daily shot rather than a weekly one. Its brand names are Victoza, for diabetes, and Saxenda, for weight loss. It was the first GLP-1 ever approved specifically to treat obesity.
How it works
It tickles the GLP-1 receptor to slow stomach emptying, quiet appetite, and let insulin out only when sugar rises. The biology is identical to its newer cousins; the difference is a fatty-acid tweak that keeps it active for about 13 hours — hence the daily dosing instead of weekly.
What people report
- ✦Real weight loss, around 6-8% on average in clinical trials
- ✦Cardiovascular risk reduction in diabetic patients
- ✦Decades of safety data as the grandparent of the class
- ✦Pediatric approval for teens, with newer data in younger kids
Typical use
A daily injection, taken as an ongoing medication. The dose is raised slowly over several weeks to limit stomach upset.
Dosing reference
Daily injection, dose managed by a clinician. Generic versions now exist, which have slowly begun to bring the price down.
Reference only — not a recommendation. Verify via primary sources.
Watch for
The daily shot is the main practical drawback — weekly drugs give more weight loss with fewer pokes. Side effects are the same gut issues as the rest of the class. It has quietly become the 'insurance forced' option when newer drugs aren't covered.
Notes
Without liraglutide's commercial success, semaglutide might never have been built. Consider it the molecule that started the era.
Educational content — not medical advice.